Triple therapy shows promise for intermediate liver cancer
NCT ID NCT05332496
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a three-pronged approach for intermediate-stage liver cancer: a procedure that blocks blood flow to the tumor (TACE), immunotherapy drugs that help the immune system fight cancer, and targeted drugs that stop blood vessel growth. Over 900 patients participated. The goal was to see if this combination improves how long patients live without their cancer getting worse. The study is complete, but full results are still pending.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PD-1/PD-L1 inhibitors (e.g., atezolizumab, pembrolizumab) and VEGF-TKI/bevacizumab (e.g., sorafenib, lenvatinib)
What this could lead to
If successful, this combination could offer a new standard treatment to control intermediate-stage liver cancer and extend survival without needing lifelong medication.
What could go wrong
This is a completed study, but results are not yet published. The combination may cause serious side effects, and not all patients may benefit equally.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gao-Jun Teng
Nanjing, China
-
Zheng-Gang Ren
Nanjing, China